Ca Channel Inhibitors: Conotoxin
Brief Introduction of Ca Channel Inhibitors: Conotoxin
Conotoxins, a kind of bioactive peptide toxin obtained from the marine gastropod mollusk conus. They can selectively act on ion channels and other protein receptors, thus affecting nerve conduction and producing different physiological effects. Conotoxins are small peptides with a length of 10-40 amino acid residues that contain multiple disulfide bridges. According to their target sites, they can be classified into α, ω, μ, δ, κ, and μ/ ν and other types. The ω-conotoxins specifically block voltage-sensitive calcium channels (VGCCs). Conotoxins have been proven to have potential applications in a variety of pathological conditions and have become a powerful therapeutic tool.
Calcium entry mediated by VGCCs is the initial trigger for the release of neurotransmitters from presynaptic nerve terminals. VGCCs are important targets for the treatment of pain, stroke, epilepsy, migraine, and hypertension due to their important role in calcium signaling.
Mechanisms of Conotoxin Inhibition of VGCCs
Multiple and complex pathophysiological mechanisms are responsible for the development and maintenance of chronic pain. Altered N-type VGCC function in sensory neurons has been implicated as one of these mechanisms, suggesting that VGCCs inhibitors or modulators could be developed into useful drugs to treat neuropathic pain. The main mechanism that ω-conotoxins specifically blocks VGCCs is by blocking the channel pore, which is accomplished by tight binding of the toxin to the channel pore. This binding reduces calcium influx through the channels presumably by occluding the pore.
Fig.1 Putative mechanisms of action of VGCC-inhibiting conotoxins. (Mohammadi, 2015)
Therapeutic Use of Conotoxins
It is well known that the conotoxins could selectively bind closely to relevant molecular targets which is an important advantage of these marine conopeptides. Another advantage of conotoxins is the diversity of targets, as they can act on ion channels, several G-protein coupled receptors, and ligand-gated receptors. These properties make them excellent candidates for the development of new biological compounds and derivatives to combat pathologies, such as pain, stroke, and convulsive diseases.
The ω-conotoxins are the most widely used conus peptide family in neuroscience. They have been intensively studied to inhibit neurotransmitter release and treat inflammatory and chronic neuropathic conditions. Typically, neuronal CaV channels have potential to be used as targets for treatments of pain and the selectivity of conotoxins for these channels makes conopeptides a valuable therapeutic tool. Owing to their stable structure, small size, and target specificity, conotoxins are considered an ideal molecular probe for target validation and peptide drug discovery.
The wide applications of conotoxins require improvements to enhance their transport across the blood-brain barrier and modification to improve their chemical stability.
Fig. 2 Main pharmacological properties of conotoxins. (Mir, 2016)
Some conotoxins are very promising. Creative Biolabs has a professional platform to provide the leading services related to neurotoxins. We are a multidisciplinary, qualified, and experienced team. If you want to know more, please do not hesitate to contact us for more detailed information.
References
- Mohammadi, S.A.; et al. Conotoxin Interactions with α9α10-nAChRs: Is the α9α10-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management? Toxins (Basel). 2015, 7: 3916-32.
- Mir, R.; et al. Conotoxins: Structure, Therapeutic Potential, and Pharmacological Applications. Curr Pharm Des. 2016, 22: 582-9.
- iNeuMab™ Anti-FGFR1 Antibody (NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Anti-CD20 Antibody (NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)